- A Worldwide Cancer Registry Enrolling Participants Profiled With a Next-Generation Sequencing Test — Recruiting • Oncology • NCT04529122.
- WAYFIND-R is a registry that aims to capture high-quality real-world data linking next-generation sequencing, treatments and outcomes from cancer patients diagnosed with a solid tumour. The WAYFIND-R has three main overarching objectives: 1. To provide a platform to support the design and….
- Sponsor: Hoffmann-La Roche.
Verify eligibility, endpoints and current status on the original source registry before acting on this summary.
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
WAYFIND-R is a registry that aims to capture high-quality real-world data linking next-generation sequencing, treatments and outcomes from cancer patients diagnosed with a solid tumour. The WAYFIND-R has three main overarching objectives: 1. To provide a platform to support the design and conduct of clinical and epidemiological research; 2. To develop an evidence-generation platform to better understand health outcomes and cancer care processes; and 3. To characterize the treatments and clinical course of solid tumor cancers in patients who have undergone NGS testing.
- : * Participant is an adult (according to the age of majority as defined by local regulations) * Participant is currently diagnosed with any type of solid tumour cancer, at any stage of the disease, at the enrollment date (informed consent date) * Participant has undergone NGS testing, no longer than 3 months prior to the enrollment date, irrespective of the availability of test results * Informed consent has been obtained from the participant or legally authorized representative, as per local regulations
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.